Matthew Mackey

from Deerfield, NH

Get Report

Connected to:

Matthew Mackey Phones & Addresses

Tetrahydropyrazolopyrimidine Compounds
view source
US Patent:

20130324547, Dec 5, 2013
Filed:

May 31, 2013
Appl. No.:

13/907202
Inventors:

Roch Boivin - North Chelmsford MS, US
Eric Carlson - Merrimack NH, US
Atsushi Endo - Andover MA, US
Hans Hansen - Somerville MA, US
Lynn D. Hawkins - Concord MA, US
Sally Ishizaka - Weston MA, US
Matthew Mackey - Melrose MA, US
Sridhar Narayan - Belmont MA, US
Takashi Satoh - Andover MA, US
Shawn Schiller - Haverhill MA, US
International Classification:

C07D 471/04
US Classification:

51425216, 544281, 5142593
Abstract:

Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis

Tetrahydropyrazolopyrimidine Compounds
view source
US Patent:

20200347050, Nov 5, 2020
Filed:

Apr 10, 2020
Appl. No.:

16/845594
Inventors:

- Tokyo, JP
Eric CARLSON - Merrimack NH, US
Atsushi ENDO - Andover MA, US
Hans HANSEN - Somerville MA, US
Lynn D. HAWKINS - Concord MA, US
Sally ISHIZAKA - Weston MA, US
Matthew MACKEY - Melrose MA, US
Sridhar NARAYAN - Belmont MA, US
Takashi SATOH - Andover MA, US
Shawn SCHILLER - Haverhill MA, US
Assignee:

Eisai R&D Management Co., Ltd. - Tokyo
International Classification:

C07D 471/04
C07D 487/04
A61K 31/519
A61K 31/55
Abstract:

Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Tetrahydropyrazolopyrimidine Compounds
view source
US Patent:

20180273532, Sep 27, 2018
Filed:

Dec 14, 2017
Appl. No.:

15/841767
Inventors:

- Tokyo, JP
Eric Carlson - Merrimack NH, US
Atsushi Endo - Andover MA, US
Hans Hansen - Somerville MA, US
Lynn D. Hawkins - Concord MA, US
Sally Ishizaka - Weston MA, US
Matthew Mackey - Melrose MA, US
Sridhar Narayan - Belmont MA, US
Takashi Satoh - Andover MA, US
Shawn Schiller - Haverhill MA, US
Assignee:

EISAI R&D MANAGEMENT CO., LTD. - TOKYO
International Classification:

C07D 471/04
A61K 31/55
C07D 487/04
A61K 31/519
Abstract:

Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Tetrahydropyrazolopyrimidine Compounds
view source
US Patent:

20160339032, Nov 24, 2016
Filed:

Aug 10, 2016
Appl. No.:

15/233520
Inventors:

- Tokyo, JP
Eric Carlson - Merrimack NH, US
Atsushi Endo - Andover MA, US
Hans Hansen - Somerville MA, US
Lynn D. Hawkins - Concord MA, US
Sally Ishizaka - Weston MA, US
Matthew Mackey - Melrose MA, US
Sridhar Narayan - Belmont MA, US
Takashi Satoh - Andover MA, US
Shawn Schiller - Haverhill MA, US
International Classification:

A61K 31/519
A61K 31/55
Abstract:

Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis

Tetrahydropyrazolopyrimidine Compounds
view source
US Patent:

20160030430, Feb 4, 2016
Filed:

Jul 22, 2015
Appl. No.:

14/806174
Inventors:

- TOKYO, JP
Eric Carlson - Merrimack NH, US
Atsushi Endo - Andover MA, US
Hans Hansen - Somerville MA, US
Lynn D. Hawkins - Concord MA, US
Sally Ishizaka - Weston MA, US
Matthew Mackey - Melrose MA, US
Sridhar Narayan - Belmont MA, US
Takashi Satoh - Andover MA, US
Shawn Schiller - Haverhill MA, US
International Classification:

A61K 31/519
Abstract:

Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis